Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10976-10982

  Beretta, Giovanni L ^a   Petrangolini, Giovanna ^a   De Cesare, Michelandrea ^a   Pratesi, Graziella ^a   Perego, Paola ^a   Tinelli, Stella ^a   Tortoreto, Monica ^a   Zucchetti, Massimo ^b   Frapolli, Roberta ^b   Bello, Ezia ^b   Manzotti, Carla ^c   Fontana, Gabriele ^c   Bombardelli, Ezio ^c   Battaglia, Arturo ^d   Samorì, Cristian ^d   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INDENA S P A   (Italy)

^d Istituto per la Sintesi Organica e la Fotoreattività   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; IDN 5174; IDN 6080; IDN 6083; IRINOTECAN; LACTONE; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA CLEAVAGE; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG POTENCY; ENZYME ANALYSIS; ENZYME PURIFICATION; FEMALE; GROWTH INHIBITION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; HUMANS; LACTONES; MICE; SPERMIDINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845344031     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2158     Document Type: Article

References (32)

1. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topo I. J Biol Chem 1985;260:14873-8.
2. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topo I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
3. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topo I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
4. Chourpa I, Riou JF, Millot JM, Pommier Y, Manfait M. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topo I cleavage sites on DNA. Biochemistry 1998;37:7284-91.
5. Burke TG, Munshi CB, Mi Z, Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995;84:518-9.
6. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92.
7. Loos WJ, Verweij J, Gelderblom HJ, et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs 1999;10:705-10.
8. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20.
9. Wang X, Zhou X, Hecht SM. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 1999;38:4374-81.
10. Pirillo A, Verotta L, Gariboldi P, Torregiani E, Bombardelli E. Constituents of Nothapodytes foetida. J Chem Soc Perkin Trans 1995;1:583.
11. Manning GS, Ray J. Counterion condensation revisited. J Biomol Struct Dyn 1998;16:461-76.
12. Holley JL, Mater A, Wheelhose RT, et al. Targeting of tumor cells and DNA by a chlorambucil spermidine conjugate. Cancer Res 1992;52:4190-5.
13. Cullis PM, Merson-Davis L, Weaver R. Mechanism and reactivity of chlorambucil and chlorambucil-spermidine conjugates. J Am Chem Soc 1995;117:8033-4.
14. Stark PA, Thrail BD, Meadows GG, Abdel-Monem MM. Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents. J Med Chem 1992;35:4264-9.
15. Holley JL, Mater A, Cullis PM, et al. Uptake and cytotoxicity of novel and nitroimidazole-polyamine conjugates in Ehrlich ascite tumour cells. Biochem Pharmacol 1992;43:763-9.
16. Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin. Bioorg Med Chem Lett 2004;14:1519-22.
17. Heston WD, Uy L, Fair WR, Covey DF. Cytotaric activity of aziridinyl putrescine enhanced by polyamine depletion with α-difluoromethylornithine. Biochem Pharmacol 1985;34:2409-10.
18. 1- and N-8-aziridinyl analogues of spermidine. Cancer Res 1994;54:742-8.
19. Eiseman JL, Rogers FA, Guo Y, et al. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res 1998;58:4864-70.
20. Delcros J-G, Tomasi S, Carrington S, et al. Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine. J Med Chem 2002;45:5098-111.
21. Suzuki I, Shigenaga A, Nemoto H, Shibuya M. Synthesis and DNA damaging ability of enediynepolyamine conjugates. Tetr Letters 2004;45:1955-9.
22. Beretta GL, Binaschi M, Zagni E, Capuani L, Capranico G. Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain. Cancer Res 1999;59:3689-97.
23. Dallavalle S, Ferrari A, Biasotti B, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 2001;44:3264-74.
24. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1988;58:109-13.
25. Pratesi G, Manzotti C, Tortoreto M, Prosperi E, Zunino F. Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori 1989;75:60-5.
26. Marchesini R, Colombo A, Caserini C, et al. Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 1996;66:342-6.
27. Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Investig Drugs 2004;13:269-84.
28. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem 2004;12:1585-604.
29. Hsiang YH, Liu LF, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989;49:4385-9.
30. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994;54:1431-9.
31. Hautefaye P, Cimetière B, Pierrè A, et al. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg Med Chem Lett 2003;13:2731-5.
32. Yaegashi T, Sawada S, Nagata H, Furuta T, Yokokura T, Miyasaka T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives. A-ring-substituted 7-ethyl-camptothecins and their E-ring-modified water-soluble derivatives. Chem Pharm Bull 1994;42:2518-25.